Nexalin Technology (NXL) shares were down 15% Friday after the medical device company filed a preliminary prospectus for the potential sale of nearly 2.8 million shares available to Maxim Partners by exercising warrants issued to the private equity firm during the company's initial public offering in September 2022.
Maxim can exercise warrants to buy nearly 2.7 million shares at $4.15 apiece anytime within three years of their 2022 issue. Nexalin's stock topped the exercise price for the first time ever on Nov. 15 and traded as high as $4.18 per share as recently as Dec. 13 but closed Thursday at $3.06 and were extending their retreat on Friday.
Nexalin would receive around $11 million in gross proceeds if Maxim exercised all of its available warrants, and is not due to receive any proceeds from the sale of any shares by Maxim, according to the company's prospectus.
Price: 2.60, Change: -0.46, Percent Change: -15.00
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。